Takeda Pharmaceutical (TAK) Non-Current Debt: 2018-2025
Historic Non-Current Debt for Takeda Pharmaceutical (TAK) over the last 8 years, with Mar 2025 value amounting to $26.0 billion.
- Takeda Pharmaceutical's Non-Current Debt fell 13.93% to $26.0 billion in Q1 2025 from the same period last year, while for Mar 2025 it was $26.0 billion, marking a year-over-year decrease of 13.93%. This contributed to the annual value of $26.0 billion for FY2025, which is 16.12% down from last year.
- Takeda Pharmaceutical's Non-Current Debt amounted to $26.0 billion in Q1 2025, which was down 13.93% from $30.2 billion recorded in Q1 2024.
- In the past 5 years, Takeda Pharmaceutical's Non-Current Debt registered a high of $43.6 billion during Q1 2021, and its lowest value of $26.0 billion during Q1 2025.
- Its 3-year average for Non-Current Debt is $28.9 billion, with a median of $30.2 billion in 2024.
- Per our database at Business Quant, Takeda Pharmaceutical's Non-Current Debt grew by 5.30% in 2021 and then fell by 18.23% in 2022.
- MRQ analysis of 5 years shows Takeda Pharmaceutical's Non-Current Debt stood at $43.6 billion in 2021, then fell by 18.23% to $35.6 billion in 2022, then decreased by 14.24% to $30.6 billion in 2023, then fell by 1.17% to $30.2 billion in 2024, then fell by 13.93% to $26.0 billion in 2025.
- Its Non-Current Debt was $26.0 billion in Q1 2025, compared to $30.2 billion in Q1 2024 and $30.6 billion in Q1 2023.